Skip to main content

Solid Biosciences Inc.

corporate_fare Company Profile

Solid Biosciences Inc.

SLDB·NASDAQ·Life Sciences·CIK 0001707502

Solid Biosciences Inc. is a life sciences company dedicated to developing gene therapy candidates for genetic neuromuscular and cardiac diseases. The company's portfolio includes SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich's ataxia, SGT-501 for Catecholaminergic polymorphic ventricular tachycardia, and SGT-601 for TNNT2-mediated dilated cardiomyopathy. These candidates are at various stages of development with different investment levels. Solid Biosciences focuses on rare neuromuscular and cardiac diseases, integrating internal capabilities such as a vector core, validated animal models, optimized expression cassettes, novel capsids, and regulatory expertise. The company also collaborates with leaders in clinical and research fields. Its business model prioritizes identifying and developing therapies for underserved patients with potentially fatal neuromuscular and cardiac diseases, building innovative libraries of delivery capsids and other enabling technologies, and collaborating with leading experts in the field. The company's mission is to treat and change the course of neuromuscular and cardiac diseases at all stages.

Solid Biosciences Inc. (NASDAQ:SLDB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for SLDB at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • RA Capital Management Increases Stake in Solid Biosciences with $27.3M Investment in Private Placement and Open Market Buys
  • Solid Biosciences Secures $240M Private Placement, Extends Cash Runway Amid Significant Dilution
  • Solid Biosciences Secures $240M Oversubscribed Private Placement

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$174.32M
Diluted EPS
-$1.99
Op. Cash Flow
-$156.29M
Free Cash Flow
-$157.44M
Operating Income
-$179.21M
Cash & Equivalents
$59.9M
Debt / Equity
0.00×
Shares Outstanding
78.97M sh
Source: 10-K · filed 2026-03-19 · accession 0001193125-26-115928
$6.25
52-week range · as of 2026-11-04 $3.79 – $11.45
Market cap
$697.57M
Volume
1.6M (1.1× avg)
3-mo avg 1.4M
Live data · 2026-11-22 12:52 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SLDB - Filings & News (Page 2)

SLDB
Mar 10, 2026, 4:38 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $8.25
Real-time Price: $6.25 info
Change: -$2.00 (-24%) info
Market Cap: $697.566M info
SLDB
Mar 06, 2026, 4:36 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.85
Real-time Price: $6.25 info
Change: -$0.600 (-9%) info
Market Cap: $697.566M info
SLDB
Mar 06, 2026, 8:32 AM EST
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $6.22
Real-time Price: $6.25 info
Change: +$0.030 (+0.48%) info
Market Cap: $697.566M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets